Diabetes in Pregnancy Nursing CE Course

ucose production decreases, further decreasing fasting glucose levels. This puts insulin-dependent individuals at a higher risk of hypoglycemia during pregnancy (ADA, 2024; Mittal et al., 2025).

During pregnancy, there are complex changes in glucose metabolism, insulin production, and metabolic homeostasis. Glucose is the primary form of energy for the developing fetus and is transported across the placenta through carrier-mediated diffusion. Because of this process, the glucose level in the fetus is directly related to the glucose level in the pregnant individual. As the first trimester ends, the fetus starts secreting insulin around the 10th week of gestation. Therefore, as maternal blood glucose increases, the blood glucose level in the fetus increases, and the amount of insulin secreted by the fetus increases (Choudhury & Rajeswari, 2021).

GDM occurs when there is any degree of glucose intolerance with an onset during pregnancy caused by pancreatic β-cell dysfunction and the release of hormones from the placenta. Lactogen is the primary hormone released by the placenta that contributes to glucose intolerance; however, growth hormone, prolactin, corticotropin-releasing hormone, and progesterone are all contributory (Mittal et al., 2025).

Pregestational Diabetes

Incidence

Pregestational diabetes is present only in 1% to 2% of all pregnancies in the United States. Among those giving birth in 2021, the overall pregestational diabetes rate was 10.9 per 1,000 births, an increase of 27% from 2016. Recent data indicate that T2DM is more prevalent among pregnant patients with pregestational diabetes. Specifically, approximately 76% of patients with pregestational diabetes have preexisting T2DM, while about 24% have T1DM. Even if the individual is not insulin dependent before pregnancy, many individuals with pregestational diabetes become insulin dependent during pregnancy due to the metabolic changes that occur (Gregory & Ely, 2023; Hart et al., 2021).

Maternal Risk and Complications During Pregnancy

Pregnant individuals with diabetes are at an increased risk of hypertension, preeclampsia, preterm birth, and mortality. The likelihood of experiencing diabetes-related complications during pregnancy depends crucially on the time since diagnosis and how well the patient managed their blood glucose levels before pregnancy. Individuals with DM-induced nephropathy, hypertension, or poor glycemic control before pregnancy are more likely to develop preeclampsia. Polyhydramnios (increased amniotic fluid) can occur in pregnant individuals with DM. Although usually mild, the increased fluid level may cause discomfort, premature contractions and rupture of membranes, and preterm birth in severe cases. Infections are also more common in individuals with DM that are pregnant. Vaginal infections, particularly vaginitis, and urinary tract infections (UTIs) are more prevalent in these individuals. Active infection is a concern for these individuals since it can lead to diabetic ketoacidosis (DKA). DKA occurs due to the accumulation of ketones in the blood due to hyperglycemia and can lead to metabolic acidosis, a medical emergency requiring hospitalization. Symptoms of DKA include decreased alertness, dry mouth, polydipsia, polyuria, headache, muscle stiffness, nausea or vomiting, and fruity-smelling breath. Unlike nonpregnant individuals with DM, who typically experience DKA when blood glucose levels exceed 350 mg/dL, a blood glucose level slightly above 200 mg/dL can lead to DKA in pregnant individuals with DM (Bapayeva et al., 2022; Ruiz et al., 2024).

Pregnancy exacerbates diabetes-related complications, particularly retinopathy and nephropathy. Poorly controlled pregestational DM can lead to severe organ damage that may become life-threatening. Approximately 1 in 12 pregnant individuals with preexisting diabetes without retinopathy may develop some form of retinopathy during pregnancy. Retinopathy can progress during pregnancy, especially if hypertension or poor glycemic control continues during pregnancy. Individuals at risk for retinopathy should obtain a baseline eye examination during the first trimester and be closely monitored throughout the pregnancy. Nephropathy (defined as microalbuminuria greater than 300 mg/24 hours with or without impaired renal function) is also present in 2% to 5% of pregnancies complicated by pregestational DM. End-stage renal disease can occur in individuals with severe proteinuria during pregnancy (>3 g per 24 hours) or creatinine levels above 1.5 mg/dL. Aggressive management with antihypertensives can lead to better outcomes. While specific incidence rates vary, studies have shown that acute kidney injury complicates approximately 0.08% of pregnancy-related hospitalizations. (Afifi & Salah, 2022; Guillen et al., 2024; Varughese & Jacob, 2025).

Interventions

Antepartum

Diet. Individuals with DM should undergo nutrition counseling with a diabetic educator or dietician at their initial diagnosis. Due to the changes in the metabolic process that pregnancy causes, the individual must be further educated on how to incorporate necessary changes into their diet for glycemic control and the increased caloric demands of the pregnancy. Weight gain is expected and considered normal if it aligns with the acceptable amount for gestational age. The nutritional goals include weight changes consistent with a normal pregnancy, prevention of ketoacidosis, and stabilization of blood glucose levels (ADA, 2024).

Dietary recommendations are based on the pregnant individual’s body mass index (BMI), prepregnancy weight, and the trimester of the pregnancy. For individuals with a BMI of 18.5 to 24.9, the recommended intake is 30 to 34 kcal/kg of ideal body weight daily. For individuals with a BMI of 25 to 29.9, the recommended intake is 25 to 29 kcal/kg of ideal body weight daily. For individuals with a BMI greater than 30, the recommended intake is 24 kcal/kg of their actual body weight per day. This equates to approximately 2200 calories per day during the first trimester and 2500 calories per day in the second and third trimesters. This total caloric intake should be spread throughout the day (three meals and one evening snack or three smaller meals and two to three snacks). The individual must not skip meals and eat at least every 3 to 4 hours to prevent hypoglycemia or blood glucose fluctuations. The evening snack should include at least 25 g of complex carbohydrates with protein or fat to prevent hypoglycemia or starvation ketosis during the night. The ideal diabetic diet should be composed of 40% to 50% of calories from carbohydrates, 20% protein, and 30% to 35% fat, with less than 10% from saturated fats. Complex carbohydrates high in fiber are recommended over simple carbohydrates due to their effects on regulating the individual’s blood glucose level (Vasile et al., 2021). Education for pregnant individuals with pregestational DM includes:

• follow the diet plan
• include daily food requirements recommended for all pregnant individuals
• divide daily food intake throughout the day; never skip a meal or snack
• eat a substantial bedtime snack to prevent a severe drop in blood glucose overnight
• take daily prenatal vitamins, including iron, as prescribed
• avoid foods high in refined sugar
• avoid alcohol, nicotine, and caffeine
• avoid the use of artificial sweeteners (ADA, 2024; Vasile et al., 2021; Zera & Brown, 2025)

Exercise. Regular exercise is recommended for individuals with DM; however, exercise requirements and recommendations for individuals that are pregnant with DM are limited. Exercise recommendations should be personalized and based on the patient’s clinical presentation. Regular aerobic exercise may be contraindicated during pregnancy in individuals with pregestational DM and comorbidities, including severe hypertension, advanced retinopathy, or advanced peripheral neuropathy. Exercise is also contraindicated in individuals with positive urine ketones or blood glucose readings greater than 250 mg/dL due to the risk of exercise worsening these conditions. When exercise is recommended, it should be limited to 30 minutes of aerobic exercise with resistance training most days of the week. Other activities may include a non–weight-bearing workout on a stationary bike. The best time to exercise is when blood glucose levels are rising after a meal. Blood glucose levels should be monitored closely for at least 2 hours following exercise due to the risk of delayed exercise-induced hypoglycemia (ADA, 2024; Yang et al., 2023).

Blood glucose monitoring. The ADA recommends frequent blood glucose monitoring during pregnancy, including before and after meals. The following are recommended goals for individuals with pregestational DM:

• fasting glucose less than 95 mg/dL
• preprandial (before a meal) glucose less than 100 mg/dL
• 1-hour postprandial (after a meal) glucose less than 140 mg/dL
• 2-hour postprandial glucose less than 120 mg/dL
• mean capillary glucose of 100 mg/dL
• overnight glucose levels should be above 60 mg/dL (ADA, 2024)

Another way to monitor blood glucose levels is continuous glucose monitoring (CGM). This way of monitoring blood glucose levels is especially popular with those individuals with T1DM. The ADA recommends the following blood glucose goals when using CGM for patients with T1DM:

• target range of 63 mg/dL to 140 mg/dL
• time-in-range above 70% (equates to greater than 16 hours and 48 minutes)
• time-above-range less than 25% (equates to less than 6 hours)
• time-below-range less than 4% (equates to less than 1 hour) with less than 1% of the time with a blood glucose reading less than 54 mg/dL (equates to less than 14 minutes; ADA, 2024)

There is a lack of research and evidence on CGM and targets for pregnant individuals with T2DM. The individual’s hemoglobin A1C (HbA1c) measures average blood glucose control over the previous 2- to 3-month period. Individuals with DM that become pregnant should have their HbA1c checked at least every trimester or more frequently if indicated. The target result of the HbA1c is less than 6% if achievable without significant hypoglycemia, indicating an average blood glucose of 126 mg/dL. As the pregnancy progresses, the target HbA1c may be increased to 7%. An elevated HbA1c at conception and during the first trimester has been shown to increase the risk of congenital disabilities (ADA, 2024).

       Testing for Ketonuria. In pregnant individuals with preexisting type 1 or type 2 diabetes, it is appropriate to test for ketonuria when blood glucose levels exceed 200 mg/dL. Notably, 10% to 30% of DKA cases during pregnancy have occurred with blood glucose levels below 250 mg/dL. Ketonuria testing is also recommended during episodes of illness or physiologic stress or when symptoms suggestive of ketoacidosis are present (i.e., nausea, vomiting, or abdominal pain). Patients exhibiting moderate to large amounts of ketones in the urine should promptly notify the healthcare provider as additional insulin therapy may be required to prevent or treat DKA, which constitutes both a medical and an obstetric emergency due to its potential risks to maternal and fetal health (Zera & Brown, 2025).

Medication Management. As discussed previously, insulin requirements decrease during the first trimester. In subsequent trimesters, the need for insulin increases, especially during the last trimester. The need for more insulin is caused by the placental hormones needed for the fetus’ growth. These placental hormones block the action of insulin. Individuals with T2DM managing their diabetes with diet and oral medications alone before pregnancy often need to transition to utilizing insulin for blood glucose control during pregnancy. Individuals with T1DM before pregnancy may need to administer insulin up to five times daily; those with an insulin pump will continue to utilize the pump for blood glucose control. As the pregnancy progresses, these individuals will require more insulin due to the insulin resistance that occurs during the last trimester. During pregnancy, insulin should be injected into the abdomen instead of other common injection sites on the extremities. This preference is due to the increased insulin absorption when using this site during pregnancy (ADA, 2024).

In individuals with T1DM, pregnancy will affect the amount of insulin required. Basal insulin delivered as intermediate-acting (NPH [Humulin N] or Humulin L) or long-acting insulin (such as glargine [Lantus] or detemir [Levemir]) suppresses hepatic gluconeogenesis in the fasting state and is necessary for individuals with T1DM. Bolus dosing of short-acting insulin, such as lispro (Humalog) and aspart (Novolog), is usually required with meals to mimic postprandial insulin secretion. The insulin resistance that occurs during pregnancy decreases the effectiveness of oral diabetic agents. Various categories of insulin and their onset, peak, and duration of action are listed in Table 1 (ADA, 2024; Festa et al., 2021).

Table 1

Common Insulin Preparations 

Type of Insulin	Examples	Onset of Action	Peak of Action	Duration of Action	Administration
Rapid-acting	Lispro (Humalog)	5-15 min	45-75 min	3-5 hr	It can be mixed in a syringe with NPH.
	Aspart (Novolog)	5-15 min	45-75 min	3-5 hr
Short-acting	Humulin R	30-60 min	2-4 hr	6-8 hr	It can be mixed in the syringe with NPH.
	Novolin R	30-60 min	2-4 hr	6-8 hr
Intermediate-acting	NPH (Humulin N)	~2 hr	4-12 hr	18-26 hr	It can be mixed in the syringe with rapid- or short-acting.
	Novolin N	~2 hr	4-12 hr	18-26 hr
	Humulin L	~2 hr	4-12 hr	18-26 hr
	Novolin L	~2 hr	4-12 hr	18-26 hr
Long-acting	Detemir (Levemir)	1-2 hr	None	14-24 hr	It cannot be mixed in the syringe with any other insulins.
	Glargine (Lantus)	3-4 hr	None	~24 hr

(ADA, 2024; Merck Manual, n.d.)

Fetal Surveillance. A baseline ultrasound is completed early in pregnancy to determine gestational age and fetal size. Follow-up ultrasounds are conducted as often as every 3 to 4 weeks to monitor fetal growth for signs of microsomia or macrosomia, detect hydramnios, or any other congenital abnormalities. Due to the increased risk of neural tube defects in the fetus of an individual with pregestational DM, a serum alpha-fetoprotein measurement is completed between 16 and 18 weeks of gestation, and a detailed ultrasound is completed between weeks 18 and 20. Late in the first trimester, fetal nuchal translucency (NG) measurement and maternal screening can lead to the early detection of cardiac abnormalities. A fetal echocardiogram may also be performed between weeks 20 and 22. This test is beneficial in individuals that did not control their blood glucose levels during the first trimester, indicated by an HbA1c greater than 6% at the first prenatal checkup. Individuals with pregestational DM that also have vascular disease may have doppler studies performed on the umbilical artery to screen for placental compromise (ADA, 2024).

More fetal monitoring occurs during the third trimester, when the risk of fetal compromise is the highest. In addition to testing, the pregnant individual should be taught how to self-monitor fetal movement by performing kick counts starting at 28 weeks. In week 32, nonstress tests (NSTs) should be conducted twice weekly. NSTs are the primary method used to evaluate the well-being of the fetus. Individuals with vascular disease or poor glucose control often start NSTs in week 28. If the NST is nonreactive, a biophysical profile or contraction stress test should be performed. It is recommended that individuals with controlled pregestational DM deliver between 39 0/7 and 6/7 weeks. Individuals with poorly controlled pregestational DM should deliver between 36 0/7 weeks and 38 6/7 weeks (American College of Obstetricians and Gynecologists [ACOG], 2021).

Intrapartum

Glycemic control in patients with pregestational DM remains essential even during labor. Hyperglycemia during labor can lead to fetal hypoxemia and neonatal hypoglycemia. Many factors can affect blood glucose levels during labor, including increased metabolic demands, food restriction, and infusion of intravenous (IV) fluids containing dextrose. An intrapartum glucose target of 70 to 110 mg/dL is recommended. In individuals with preexisting DM, the intrapartum interventions change based on which stage of labor the individual is currently in and whether they have T1DM or T2DM. During latent labor, if the individual can still eat and drink unrestricted, blood glucose monitoring follows the individual’s antepartum monitoring frequency. Individuals with T1DM will continue to need basal, preprandial, and correctional insulin doses. If oral intake is reduced from normal, a reduction of 20% to 30% of the patient’s home insulin dose may be necessary to prevent hypoglycemia. Once oral intake is restricted in an individual with T2DM, blood glucose is monitored at least every 4 hours, with insulin administered when indicated based on a sliding scale. If the individual is still taking oral antihyperglycemic medications, they are discontinued once the individual is admitted to the hospital (ADA, 2024; Davis et al., 2025).

Once active labor begins, blood glucose levels are monitored more closely due to the increased stress on the body and the complications that can occur if blood glucose levels are not controlled during this stage. Once an individual with T1DM begins active labor, or food is restricted even if still in the latent phase, blood glucose monitoring increases to hourly, and dextrose-containing IV fluids and a continuous insulin infusion are indicated. These infusions are titrated based on blood glucose levels following facility protocol. The continuous insulin infusion is started first; dextrose-containing IV fluids are initiated once the blood glucose level drops below 160 mg/dL. Any further increase in blood glucose should be managed by titrating the insulin infusion (ADA, 2024; Joint British Diabetes Societies for Inpatient Care, 2023)

Once an individual with T2DM enters the active phase of labor, blood glucose checks occur every 2 to 4 hours. If the initial check is above 200 mg/dL, a continuous IV insulin infusion is initiated following a standard protocol. If the initial reading is less than 200 mg/dL, subcutaneous insulin is administered following a sliding scale. A continuous IV insulin infusion is initiated if the patient’s blood glucose readings are consistently above 125 mg/dL over multiple checks. Once the IV insulin infusion is initiated, the frequency of blood glucose checks increases to every 1 to 2 hours. Dextrose-containing IV fluids are started once the patient’s blood glucose level drops below 160 mg/dL if on IV insulin or below 125 mg/dL if on subcutaneous insulin. Like above, any future increases in blood glucose are managed by titrating the insulin dose. In either scenario, once a continuous insulin infusion begins, another IV line should be initiated to administer oxytocin (Pitocin), antibiotics, magnesium sulfate, or analgesics. It is also recommended that Lactated Ringers be given as maintenance fluid once an insulin infusion begins (ADA, 2024; University of Cincinnati, 2023).

Cesarean delivery. For patients on insulin undergoing planned cesarean delivery, the procedure should be completed early in the morning. Patients should continue the usual NPH dose the night before. For those using long-acting basal insulin, it is recommended to reduce the dose by 20% to 50% based on recent fasting glucose levels. Insulin pump users should maintain basal rate unless prone to early morning hypoglycemia, in which case the overnight rate should be reduced by 20% to 50%. For patients on metformin undergoing a planned cesarean delivery, the medication should be held the morning of the procedure. Patients scheduled for a cesarean delivery managed with solely nutritional therapy are treated using the same standards as a pregnant individual without diabetes (Powe, 2024).

Postpartum

During the postpartum period, there is an increased risk of the individual experiencing hypoglycemia due to the rapid drop in diabetogenic placental hormones. In the immediate recovery period, individuals with T1DM should have their basal IV insulin dose decreased by 50%. Lactated Ringers (if being used as maintenance fluid) and dextrose infusions should continue. For individuals with T2DM, the IV insulin dose should be reduced by 50% or discontinued if blood glucose results are within normal limits. For all individuals with pregestational DM, blood glucose checks should be completed hourly during the recovery period. The individual should also be encouraged to breastfeed due to the positive effects on blood glucose control (Raets et al., 2023; Ringholm et al., 2022).

Gestational Diabetes Mellitus

Incidence

GDM affects about 14% of pregnant individuals worldwide, with increasing trends observed across all racial and ethnic groups. This increase has been attributed to the rise in overweight and obese individuals as well as advancing maternal age, sedentary lifestyles, and poor dietary habits. Enhanced screening and diagnostic practices may also lead to higher reported prevalence rates (ADA, 2024; International Diabetes Federation, 2021; Zhou et al., 2022).

Risk Factors

GDM is more likely to occur in Hispanic, African American, Indigenous Peoples, Asian, and Pacific Islander individuals. Once an individual is diagnosed with GDM, they are at an increased risk of developing GDM in future pregnancies. Other nonmodifiable risk factors include a family history of a first-degree relative with T2DM, polycystic ovarian syndrome (PCOS), a past pregnancy that resulted in unexplained intrauterine fetal demise (IUFD) or fetal macrosomia, and maternal age above 35. Modifiable risk factors include being overweight (prepregnancy BMI greater than 25), hypertension, glycosuria (glucose in the urine), low high-density lipoprotein (HDL), triglycerides greater than 250, and HbA1c greater than 5.7% (ADA, 2024; Wang et al., 2023a; Zhou et al., 2022).

Screening

Different organizations have recommendations that address the timing of screening and screening procedures for GDM. For the average patient, GDM screening occurs between 24 and 28 weeks, when glucose intolerance begins. The ADA and ACOG recommend early screening before 24 weeks for patients with an increased risk of T2DM, including those with GDM in a previous pregnancy, HbA1c greater than 5.7%, a first-degree relative with T2DM, history of cardiovascular disease, hyperlipidemia, physical inactivity, and controlled or uncontrolled hypertension. The US Preventive Services Task Force (USPSTF) supports screening at 24 weeks or later but does not recommend for or against early screening in asymptomatic individuals due to insufficient evidence. (USPSTF, 2021; Women’s Preventative Services Initiative, 2023).

Two oral glucose tolerance tests (OGTTs) are used to screen patients for GDM, the 1-step OGTT and the 2-step OGTT. The ACOG recommends the 2-step approach to GDM screening, while the ADA and International Association of the Diabetes and Pregnancy Study Groups (IADPSG) supports the 1-step OGTT. The 1-step approach simplifies the screening process since only one diagnostic test is used. For the 1-step OGTT, the individual must fast (nothing to eat or drink except for sips of water) for at least 8 hours before arriving at the lab. Once a fasting blood sample is obtained, a solution containing 75 g of glucose is administered orally. Once the glucose solution is administered, a blood sample is obtained at 1- and 2 hours post glucose intake. Abnormal results are as follows:

• fasting glucose ≥ 92 mg/dL
• 1-hour glucose ≥ 180 mg/dL
• 2-hour glucose ≥ 153 mg/dL (ADA, 2024)

The 2-step OGTT is the most widely used test for identifying individuals with GDM in the United States. During the first step, a solution containing 50 g of glucose is administered orally. The patient does not need to be fasting, so this test can be completed at any time of day. A blood sample is obtained one hour after administration of the glucose solution. Different thresholds are used to determine if the test is positive based on provider or facility guidelines; however, most institutions consider the test positive if the blood glucose level after 1 hour is greater than 130 mg/dL or 140 mg/dL. If the first step is positive, the second step is completed on a different day. In preparation for the second step, or 3-hour OGTT, the individual must fast for at least 8 hours before testing. A blood sample is obtained upon arrival at the lab to determine the fasting blood glucose level. The individual is then given a solution containing 100 g of glucose to drink. Blood samples are then taken at 1, 2, and 3 hours following administration of the glucose solution. A 3-hour OGTT is considered positive if the individual’s blood glucose results at two different points are above the threshold. Two guidelines are commonly followed in the United States to determine the threshold of blood glucose levels (refer to Table 2). If the patient has two positive results during the 3-hour OGTT, they are considered to have GDM (Coustan et al., 2021).

Table 2

3-Hour OGTT Diagnostic Guidelines

	Carpenter and Coustan (plasma or serum)	National Diabetes Data Group (plasma)
Fasting	Greater than 94 mg/dL	Greater than 104 mg/dL
One hour	Greater than 179 mg/dL	Greater than 189 mg/dL
Two hours	Greater than 154 mg/dL	Greater than 164 mg/dL
Three hours	Greater than 139 mg/dL	Greater than 145 mg/dL

                                                                                                (ACOG, 2018; Coustan et al., 2021)

Interventions

Antepartum

Once a diagnosis of GDM is confirmed, treatment and lifestyle changes are implemented as quickly as possible to mitigate potential effects on the individual and the developing fetus. Unfortunately, this quick turnaround does not allow much time for the pregnant individual to come to terms with their diagnosis. Given the psychological impact, it’s crucial for healthcare providers to offer comprehensive support that addresses both medical and emotional needs. This includes providing clear information about GDM, involving patients in decision-making, and offering resources for mental health support. Such an approach can help individuals adjust to their diagnosis and adhere to treatment plans effectively (Grinberg & Yisaschar-Mekuzas, 2024).

Diet. Dietary modifications are the initial treatment for GDM. Individuals with a new diagnosis of GDM should be referred to a dietician specializing in diabetic nutrition. The individual is started on a diabetic diet with a recommended daily intake based on their pregestational weight. For individuals with a healthy prepregnancy BMI, calorie needs remain unchanged during the first trimester, then typically increase by 340 calories per day in the second trimester, and 452 calories per day in the third. Those who are underweight, overweight, or obese will have personalized caloric needs determined accordingly. Carbohydrate intake should be limited to 40% of all caloric intake (Cheong et al., 2025; Durnwald, 2025).

Exercise. A moderate-intensity exercise regimen of 30 minutes per day for at least 5 days a week or a minimum of 150 minutes per week is recommended for individuals diagnosed with GDM. Safe options include brisk walking, swimming, stationary cycling, and prenatal yoga. Adherence to an exercise routine is even more critical in those individuals with a BMI of 25 or above to provide better blood sugar control and promote weight loss (ACOG, 2024a).

Glucose Monitoring. Glucose monitoring recommendations for individuals diagnosed with GDM are individualized, but blood glucose checks should occur at least four times daily. Fasting blood glucose should be checked in the morning, or upon the individual waking up. Postprandial glucose should be checked 1 to 2 hours after the start of each meal. Some providers may also recommend additional checks, such as before meals or at bedtime, especially if blood glucose levels are not well controlled. Individuals with GDM monitor their blood glucose at home and review their trends at their prenatal checkup appointments. Pharmacologic treatment should be initiated if nonpharmacologic interventions are not effectively controlling blood glucose levels (ADA, 2024; Venkatesh & Landon, 2021).

Treatment. First-line treatment for individuals diagnosed with GDM includes dietary modifications and exercise alone. Despite compliance with nonpharmacologic interventions, approximately 25% of individuals diagnosed with GDM will require insulin to regulate blood glucose levels. If lifestyle interventions do not achieve glycemic targets, pharmacologic therapy is recommended. Insulin is the preferred first-line pharmacologic treatment for GDM, as it does not cross the placenta and allows for precise glycemic control. Oral hypoglycemic agents, such as metformin (Glucophage) and glyburide (Diabeta), can be used in managing GDM. However, their use is subject to certain considerations. Metformin (Glucophage) is a biguanide that lowers hepatic glucose production and improves insulin sensitivity. It crosses the placenta but is not associated with teratogenic effects. Some studies suggest that metformin (Glucophage) may be associated with less maternal weight gain and a lower risk of neonatal hypoglycemia compared to insulin. Glyburide (Diabeta) is a sulfonylurea that stimulates pancreatic insulin secretion. It also crosses the placenta, and concerns have been raised about its association with higher rates of neonatal hypoglycemia and macrosomia compared to insulin. Due to these concerns, guidelines no longer recommend glyburide (Diabeta) as a first-line treatment for GDM. It’s important to note that while oral agents may be considered in certain situations, insulin remains the preferred pharmacologic treatment for GDM, especially when lifestyle modifications are insufficient. The glycemic targets for individuals with GDM are fasting glucose ≤95 mg/dL; 1-hour postprandial glucose ≤140 mg/dL; and 2-hour postprandial glucose of ≤120 mg/dL. Different categories of insulin and their onset, peak, and duration of action are listed in Table 1 (ADA, 2024; Kaiser Permanente, 2024).

Fetal Surveillance. When GDM is controlled with dietary modifications and exercise alone, there is minimal risk of IUFD. Due to this low risk, fetal monitoring is not increased in these individuals unless there is a comorbidity, such as hypertension, a history of IUFD, or if fetal macrosomia is suspected. Individuals with GDM complicated by comorbidities or requiring pharmacologic intervention to control blood glucose should have twice-weekly NSTs and assessments of amniotic fluid volume starting at week 32. For individuals with GDM well controlled with diet and exercise only, delivery is generally recommended between 39 0/7 weeks and 40 6/7 weeks. Expectant management up to 40 6/7 weeks is appropriate with ongoing fetal surveillance. For individuals with well-controlled GDM on medication, delivery is typically recommended between 39 0/7 weeks and 39 6/7 weeks of gestation. If glycemic control is poor or there are additional complications, earlier delivery (as early as 37 0/7 weeks) may be considered based on clinical judgment. Pregnancies should not extend beyond 41 0/7 weeks’ gestation due to increased risks, including stillbirth. Regardless of GDM management, fetal growth should be monitored, especially as the pregnancy approaches term. Ultrasound assessments can help estimate fetal weight and identify macrosomia (typically defined as estimated fetal weight ≥4,500 g), which may influence decisions regarding the mode and timing of delivery (ACOG, 2022, 2024b).

Intrapartum

The patient’s blood glucose levels should be checked hourly during labor. The ideal range is 70 to 125 mg/dL since this level decreases the risk of neonatal hypoglycemia. To maintain this level, the individual may need rapid-acting insulin continuously infused intravenously during labor. Maintaining this range may also be achieved by eliminating the infusion of IV fluids that contain dextrose. Although a diagnosis of GDM does not mean that the individual must undergo cesarean delivery, this may be necessary if the individual develops preeclampsia or if fetal macrosomia is present (Davis et al., 2025; Powe, 2024).

Postpartum

It is essential to closely monitor individuals with GDM as insulin requirements decrease rapidly in the first few postpartum days, with requirements returning to baseline within 48 hours for most individuals. Often, GDM resolves following delivery, and individuals regain the ability to regulate blood glucose levels with the same efficiency as they were able to pregestationally; however, approximately 33% of individuals with GDM are still found to have glucose intolerance or T2DM when screened at their postpartum appointment. The ACOG recommends screening individuals with GDM between 6 and 12 weeks postpartum using a 75 g 2-hour OGTT (ACOG, 2021; ADA, 2024).

Fetal Risk

Since GDM does not occur until after the first trimester, it does not usually lead to congenital disabilities, as the critical period of organ development occurs during the first trimester. However, early-onset GDM or undiagnosed preexisting diabetes can increase the risk. This increased risk was significantly associated with uncontrolled preconceptional blood sugar and elevated HbA1c levels (≥6.5%) in the first trimester. Therefore, early screening and glycemic control are crucial, especially for individuals with risk factors for diabetes (Al-Shwyiat & Radwan, 2023).

Additional Risk

GDM is a risk factor for developing T2DM, and individuals with GDM have a 35% to 60% increased risk of being diagnosed with T2DM 10 to 20 years following pregnancy. One population-based study found that 18.9% of individuals who had GDM developed T2DM within 9 years of the affected pregnancy. Due to this increased risk, individuals diagnosed with GDM during pregnancy should be screened for T2DM every 1 to 3 years. To prevent T2DM from occurring later in life, the patient can:

• maintain a BMI below 25
• increase physical activity to at least 30 minutes per day, 5 days per week
• make healthy food choices and limit fat intake (ADA, 2024; Brown et al., 2022)

A history of GDM also puts the individual at an increased risk of developing metabolic syndrome and cardiovascular disease. There has been a link between GDM and mortality following pregnancy due to cardiovascular changes and complications such as hypertension, obesity, and dyslipidemia. GDM also increases an individual’s lifetime risk of undergoing noninvasive diagnostic cardiac procedures, cardiovascular events, and hospitalizations due to cardiovascular complications (Wang et al., 2023b).

GDM can also increase an individual’s risk of developing malignancies later in life. There is a correlation between GDM and ovarian, endometrial, breast, and pancreatic cancer. GDM can also have significant effects on the eyes leading to ophthalmic disease and long-term ophthalmic morbidity. Individuals with GDM are more likely to develop glaucoma, diabetic retinopathy, or retinal detachment than those without GDM. Renal disease can also occur because of GDM. The most common disorders later in life in individuals that have had GDM include hypertensive renal disease with and without renal failure, chronic renal failure, and end-stage renal disease (Wang et al., 2023b).

Overall Implications

Infant Assessment

Infants born from individuals with diabetes may have specific outward characteristics. These infants are often oversized for their gestational age and are very plump and have full faces. These infants are also frequently born liberally covered with vernix. The placenta and umbilical cord are also often larger than average. Due to hyperbilirubinemia, the infant may appear jaundiced (Al Bekai et al., 2025).

Infants born to individuals with DM should be monitored closely. Serum levels of calcium and bilirubin should be monitored. Hypoglycemia can occur shortly after birth due to the hypertrophy and hyperplasia of the pancreatic islet cells in infants born to individuals with DM; therefore, serum blood glucose levels should be monitored closely. Feeding should be initiated within the first hour of life and blood glucose checked 30 minutes afterward. It is recommended that for asymptomatic infants, if blood glucose is <25 mg/dL in the first 4 hours of life or <35 mg/dL at 4 to 24 hours of life, intravenous (IV) glucose therapy should be initiated. If blood glucose is 25 to 40 mg/dL, increased feeding frequency and monitoring is recommended. In symptomatic infants (jitteriness, lethargy, seizures), immediate IV glucose is indicated if blood glucose is <40 mg/dL. IV glucose should be administered via a bolus of 200 mg/kg (2 mL/kg of 10% dextrose) over 1 minute. This should then be followed by a continuous infusion of 10% dextrose at 5 to 8 mg/kg/minute. Target glucose levels are >45 mg/dL in the first 48 hours of life. For infants with persistent hyperinsulinemic hypoglycemia, aim for levels >50 mg/dL (Abramowski et al., 2023; Shah et al., 2024).

Nursing care for these infants includes completing a detailed assessment and checking for congenital disabilities, injuries, or signs of cardiac or respiratory failure. The nurse should assist with thermoregulation and the introduction of carbohydrate feedings. If IV glucose is indicated, the nurse must monitor the infant for adverse reactions to the treatment and the site for signs of infiltration or phlebitis (Abramowski et al., 2023; Shah et al., 2024).

Risks and Complications

Poor glycemic control during the late stages of pregnancy can lead to fetal macrosomia. Macrosomia is defined as an infant weighing 4,000 g (8 lb 13 oz) to 4,500 g (9 lb 15 oz) or above the 90th percentile in weight for gestational age. Fetal macrosomia occurs in 40% of pregestational DM pregnancies and 50% of GDM pregnancies. As the fetus is exposed to increased glucose via the placenta, the excess is stored as body fat. Fetal macrosomia can also affect the delivery of the fetus. Due to increased size, the fetus may be unable to enter or progress down the birth canal, resulting in a cesarean section. The rate of cesarean section doubles when the fetus weighs more than 4,500 g. Those fetuses that can enter the birth canal may need to be delivered using forceps or a vacuum extractor. The provider may also need to perform an episiotomy to prevent perineal tearing because of increased fetal size. After delivery, the infant may display signs of injury from the birthing process due to its increased size. The size increase is most likely to affect the shoulders, trunk, and chest size. Due to this increase in size, shoulder dystocia occurs more frequently in these infants than in other infants with fetal macrosomia attributed to another cause. It is the most severe complication associated with fetal macrosomia. When birth weight is over 4,500 g, shoulder dystocia’s incidence increases from 19.9% to 50%. Other injuries include brachial plexus injury and palsy, fractured clavicle, or phrenic nerve palsy. The nurse must assist and monitor the infant for these injuries. Although fetal macrosomia is more common, individuals with T1DM and preexisting vascular complications or hypertension may have intrauterine growth restriction leading to fetal microsomia. This is defined as a fetus with a weight less than the 10th percentile for gestational age (Al Bekai et al., 2025; Shah et al., 2024).

After delivery, the infant is at risk for developing certain conditions due to exposure to increased glucose while in utero. The infant may experience hypoglycemia, hyperbilirubinemia, hypomagnesemia, pulmonary complications (e.g., respiratory distress syndrome), polycythemia (excessive red blood cells), hypocalcemia, and cardiac abnormalities. These complications are more prevalent when the pregnant individual’s blood glucose levels have been unmanaged and elevated throughout the pregnancy. Pulmonary complications are especially concerning and require monitoring in the special care nursery. Pulmonary complications are common in infants born to individuals with DM since lung development is delayed in these infants (Al Bekai et al., 2025; Shah et al., 2024).

The infant born to an individual with DM is also more at risk for congenital abnormalities. These include central nervous system defects such as anencephaly and spina bifida, which occur in these infants at rates 16% higher than infants born to individuals without diabetes. Cardiac defects such as ventriculoseptal defects occur in 30% of infants born to an individual with DM. Being born to an individual with DM can increase the infant’s risk of developing a metabolic disorder later in life. This includes obesity, hypertension, dyslipidemia, and glucose intolerance. Studies have found a strong correlation between exposure to increased glucose in utero and increased childhood BMI. The rate of obesity in the children of individuals with uncontrolled GDM is 7.8%. That number decreases to 4.9% when GDM is controlled; however, the rate of obesity in children of individuals with no history of GDM is 1.8%. Children born to individuals with DM treated with medication also have an increased risk of ophthalmic morbidity (Al Bekai et al., 2025; Shah et al., 2024).

Breastfeeding

Breastfeeding is recommended for all postpartum individuals as there are numerous benefits for both the individual and the infant. Breastfeeding is especially beneficial for individuals with DM. Individuals with DM experience improved metabolic function and increased insulin sensitivity while breastfeeding. Those individuals that rely on insulin to maintain euglycemia may be able to reduce the necessary dose while breastfeeding due to the metabolic improvements experienced. Research indicates that breastfeeding postpartum individuals with T1DM showed a 21% reduction in insulin requirements versus their pregestational dose. It is essential to monitor blood glucose levels to prevent hypoglycemia, especially at night when the infant is nursing and the breastfeeding individual may not be eating. It’s crucial to monitor blood glucose levels closely and consider having a snack before or during nursing sessions to maintain euglycemia. The breastfeeding individual with DM is at an increased risk of mastitis or a yeast infection of the breast, especially if blood glucose levels are not well controlled (Halawa et al., 2024; Pinho-Gomes et al., 2021).

Research has shown that breastfeeding for at least 3 months following delivery can be a protective factor against developing T2DM later in life. The longer breastfeeding is extended, the lower the risk of developing T2DM. Research indicates that breastfeeding for more than two years can reduce the risk by up to 27% compared to not breastfeeding. It is essential to address the individual’s breastfeeding concerns while educating and preparing them to succeed. Due to metabolic changes, the individual may experience delayed lactogenesis or decreased milk production in the early postpartum period. There may also be a delay in contact with the infant due to complications during delivery, delivery via cesarean section, or health concerns in the infant. The individual should also meet with a dietician to review dietary changes that will need to be made to support the caloric needs of breastfeeding while maintaining blood glucose control (Halawa et al., 2024; Pinho-Gomes et al., 2021). For additional details, please refer to the NursingCE course on Breastfeeding.

References

Abramowski, A., Ward, R., & Hamdan, A. (2023). Neonatal hypoglycemia. StatPearls. Retrieved May 12, 2025 from https://www.ncbi.nlm.nih.gov/books/NBK537105/

Afifi, A., & Salah, H. (2022). Screening of nephropathy in pregnant diabetic women. Journal of Women's Health and Gynecology, 9(203). https://jscholarpublishers.com/articles/JWHG/Screening-of-Nephropathy-in-Pregnant.pdf

Al Bekai, E., Beaini, C. E., Kalout, K., Safieddine, O., Semaan, S., Sahyoun, F., Ghadieh, H. E., Azar, S., Kanaan, A., & Harb, F. (2025). The hidden impact of gestational diabetes: Unveiling offspring complications and long-term effects. Life, 15(3), 440. https://doi.org/10.3390/life15030440

Al-Shwyiat, R. M. M., & Radwan, A. M. (2023). Fetal anomalies in gestational diabetes mellitus and risk of fetal anomalies in relation to pre-conceptional blood sugar and glycosylated hemoglobin. Journal of Mother and Child, 26(1), 73–77. https://doi.org/10.34763/jmotherandchild.20222601.d-22-00040

American College of Obstetricians and Gynecologists. (2018). ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. Obstetrics & Gynecology, 131(2), e49–e64. https://doi.org/10.1097/AOG.0000000000002501

American College of Obstetricians and Gynecologists. (2021). ACOG Committee Opinion No. 828: Indications for outpatient antenatal fetal surveillance. Obstetrics & Gynecology, 137(6), e177–e197. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/06/indications-for-outpatient-antenatal-fetal-surveillance?

American College of Obstetricians and Gynecologists. (2022). Obstetric Care Consensus No. 11: Pregnancy at age 35 years or older. Obstetrics and Gynecology, 140(2), 348–366. https://www.acog.org/-/media/project/acog/acogorg/clinical/files/obstetric-care-consensus/articles/2022/08/pregnancy-at-age-35-years-or-older.pdf

American College of Obstetricians and Gynecologists. (2024a). FAQ119: Exercise during pregnancy. Retrieved May 9, 2025 from https://www.acog.org/womens-health/faqs/exercise-during-pregnancy

American College of Obstetricians and Gynecologists. (2024b). Clinical Practice Update: Screening for gestational and pregestational diabetes in pregnancy and postpartum. Retrieved May 9, 2025 from https://journals.lww.com/greenjournal/abstract/9900/screening_for_gestational_and_pregestational.1074.aspx

American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care, 47(Suppl. 1), S1–S350. https://doi.org/10.2337/dc24-S001

Bapayeva, G., Terzic, S., Dotlic, J., Togyzbayeva, K., Bugibaeva, U., Mustafinova, M., Alisheva, A., Garzon, S., Terzic, M., & Laganà, A. S. (2022). Pregnancy outcomes in women with diabetes mellitus—The impact of diabetes type and treatment.  Menopause Review, 21(1), 37–46. https://doi.org/10.5114/pm.2022.113781

Brown, S. D., Hedderson, M. M., Zhu, Y., Tsai, A. L., Feng, J., Quesenberry, C. P., & Ferrara, A. (2022). Uptake of guideline-recommended postpartum diabetes screening among diverse women with gestational diabetes: Associations with patient factors in an integrated health system in USA. BMJ Open Diabetes Research & Care, 10(3), e002726. https://doi.org/10.1136/bmjdrc-2021-002726

Centers for Disease Control and Prevention. (2024). National diabetes statistics report. https://www.cdc.gov/diabetes/php/data-research/index.html

Chawla, R. (Ed.). (2023). RSSDI textbook of diabetes mellitus (5th ed.). Jaypee Brothers Medical Publishers.

Cheong, L., Law, L. S. C., Tan, L. Y. L., Amal, A. A. A., Khoo, C. M., & Eng, P. C. (2025). Medical nutrition therapy for women with gestational diabetes: Current practice and future perspectives. Nutrients, 17(7), 1210. https://doi.org/10.3390/nu17071210

Choudhury, A., & Rajeswari, D. (2021). Gestational diabetes mellitus—A metabolic and reproductive disorder. Biomedicine and Pharmacotherapy, 143. https://doi.org/10.1016/j.biopha.2021.112183

Coustan, D. R., Dyer, A. R., & Metzger, B. E. (2021). One-step or 2-step testing for gestational diabetes: Which is better? American Journal of Obstetrics and Gynecology, 225(6), 634–644. https://doi.org/10.1016/j.ajog.2021.05.009

Davis, M., Naseman, K., Leung, N., & Schadler, A. (2025). Evaluation of a standardized obstetrics insulin drip protocol and order set. Diabetes Spectrum, 38(1), 68–74. https://doi.org/10.2337/ds24-0011

Durnwald, C. (2025). Gestational diabetes mellitus: Glucose management, maternal prognosis, and follow-up. UpToDate. Retrieved June 10, 2025, from https://www.uptodate.com/contents/gestational-diabetes-mellitus-glucose-management-maternal-prognosis-and-follow-up

Festa, C., Fresa, R., Visalli, N., Bitterman, O., Giuliani, C., Suraci, C., Bongiovanni, M., & Napoli, A., (2021). Insulin requirements and carbohydrate-to-insulin ratio in normal weight, overweight, and obese women with type 1 diabetes under pump treatment during pregnancy: A lesson from old technologies. Frontiers in Endocrinology, 12, 610877. https://doi.org/10.3389/fendo.2021.610877

Grinberg, K., & Yisaschar-Mekuzas, Y. (2024). Assessing mental health conditions in women with gestational diabetes compared to healthy pregnant women. Healthcare, 12(14), 1438. https://doi.org/10.3390/healthcare12141438

Gregory, E. C., & Ely, D. M. (2023). Trends and characteristics in prepregnancy diabetes: United States, 2016–2021. https://stacks.cdc.gov/view/cdc/127679

Guillen, A., Shemies, R., Ankawi, G., Jesudason, S., & Piccoli, G. (2024). Women should not die of pregnancy-related acute kidney injury (PRAKI): Revealing the underwater iceberg of maternal health. Journal of Nephrology, 37, 543–546. https://doi.org/10.1007/s40620-023-01869-5

Halawa, M., Eid, Y., Ahmad, G., Hendawy, L., & Muhammad, M. (2024). Impact of diabetes in pregnancy on stage II lactogenesis among postpartum diabetic women compared to non-diabetics. QJM: An International Journal of Medicine, 117(1). https://doi.org/10.1093/qjmed/hcae070.271

Hart, B. N., Shubrook, J. H., & Mason, T. (2021). Pregestational diabetes and family planning. Clinical Diabetes, 39(3), 323–328. https://doi.org/10.2337/cd20-0062

International Diabetes Federation. (2021). IDF diabetes atlas (10th ed.). https://diabetesatlas.org/

Joint British Diabetes Societies for Inpatient Care. (2023). Managing diabetes and hyperglycaemia during labour and birth. Association of British Clinical Diabetologists. https://abcd.care/sites/default/files/site_uploads/JBDS_Guidelines_Current/JBDS_12_Managing_diabetes_and_hyperglycaemia_during_labour_and_birth_with_QR_code_February_2023.pdf

Kaiser Permanente. (2024). Gestational diabetes screening and treatment guideline. Retrieved May 9, 2025 from https://wa.kaiserpermanente.org/static/pdf/public/guidelines/diabetes-gestational.pdf

Merck Manual Professional Version. (n.d.). Onset, peak, and duration of action of human insulin preparations. Retrieved May 3, 2025 from https://www.merckmanuals.com/professional/multimedia/table/onset-peak-and-duration-of-action-of-human-insulin-preparations

Mittal, R., Prasad, K., Lemos, J., Arevalo, G., & Hirani, K. (2025). Unveiling gestational diabetes: An overview of pathophysiology and management. International Journal of Molecular Sciences, 26(5), 2320. https://doi.org/10.3390/ijms26052320

Mlynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025). Type 2 diabetes mellitus: New pathogenetic mechanisms, treatment and the most important complications. International Journal of Molecular Sciences, 26(3), 1094. https://doi.org/10.3390/ijms26031094

Mohseni, P., Khalili, D., Djalalinia, S., Mohseni, H., Farzadfar, F., Shafiee, A., & Izadi, N. (2024). The synergistic effect of obesity and dyslipidemia on hypertension: Results from the STEPS survey. Diabetology & Metabolic Syndrome, 16(81). https://pmc.ncbi.nlm.nih.gov/articles/PMC10988884/

Obaied, M., Ozer, N., Alawneh, H., & Dalmizrak, O. (2025). Implication of the HLA-DQA1, HLA-DQB1 and CTLA-4 alleles in the susceptibility to type 1 diabetes mellitus. Molecular Biology Reports, 52(330). https://link.springer.com/article/10.1007/s11033-025-10438-x

Pinho-Gomes, A., Morelli, G., Jones, A., & Woodward, M. (2021). Association of lactation with maternal risk of type 2 diabetes: A systematic review and meta-analysis of observational studies. Diabetes, Obesity, and Metabolism, 23(8), 1711–2005. https://doi.org/10.1111/dom.14417

Powe, C. E. (2024). Preexisting (pregestational) and gestational diabetes: Intrapartum and postpartum glucose management. UpToDate. Retrieved June 10, 2025, from https://www.uptodate.com/contents/preexisting-pregestational-and-gestational-diabetes-intrapartum-and-postpartum-glucose-management

Raets, L., Ingelbrecht, A., & Benhalima, K. (2023). Management of type 2 diabetes in pregnancy: A narrative review. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1193271

Ringholm, L., Nørgaard, S. K., Rytter, A., Damm, P., & Mathiesen, E. R. (2022). Dietary advice to support glycaemic control and weight management in women with type 1 diabetes during pregnancy and breastfeeding. Nutrients, 14(22), 4867. https://doi.org/10.3390/nu14224867

Ruiz, M., Lopez, D., Arnaiz, C., Viladegut, J., Baldo, J., & Sol, J. (2024). Maternal and foetal complications of pregestational and gestational diabetes: A descriptive, retrospective cohort study. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-59465-x

Shah, S. B., Bawar, S., Wajeeha, & Farooq, N. (2024). Common complications in infants born to diabetic mothers. Pakistan Journal of Health Sciences, 5(1), 84–89. https://doi.org/10.54393/pjhs.v5i01.1261

University of Cincinnati. (2023). Diabetes and pregnancy pocket guide for healthcare professionals. https://med.uc.edu/docs/default-source/obstetrics-and-gynecology-docs/ob-mfm-protocols/a-d/dapp-pocket-guide-for-healthcare-professionals_5-25-23.pdf

U.S. Preventive Services Task Force. (2021). Screening for gestational diabetes mellitus: US Preventive Services Task Force recommendation statement. JAMA, 326(6), 531–538. https://jamanetwork.com/journals/jama/fullarticle/2782858

Varughese, M. S., & Jacob, S. (2025). Diabetic retinopathy and pregnancy: An overview of the predictive risk factors for progressive worsening of eye disease during the antenatal period. Eye, 39, 812–813. https://doi.org/10.1038/s41433-025-03677-6

Vasile, F. C., Preda, A., Ștefan, A. G., Vladu, M. I., Forțofoiu, M. C., Clenciu, D., Gheorghe, I. O., Forțofoiu, M., & Moța, M. (2021). An update of medical nutrition therapy in gestational diabetes mellitus. Journal of Diabetes Research. https://doi.org/10.1155/2021/5266919

Venkatesh, K., & Landon, M. (2021). Diagnosis and management of gestational diabetes. Contemporary OBGYN, 66(5), 9–15. https://cdn.sanity.io/files/0vv8moc6/contobgyn/582617dbd9a40a32a72557b192251c2df3fd5dd1.pdf

Wang, X., Zhang, S., Yu, W., Li, G., Li, J., Ji, J., Mi, Y., & Luo, X. (2023a). Pre-pregnancy body mass index and glycated-hemoglobin with the risk of metabolic diseases in pregestational diabetes: A prospective cohort study. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1238873

Wang, Y., Mitsunami, M., Manson, J., Gaskins, A., Rich-Edwards, J., Wang, L., Zhang, C., & Chavarro, J. (2023b). Association of gestational diabetes with subsequent long-term risk of mortality. JAMA Internal Medicine, 183(11), 1204–1213. https://pubmed.ncbi.nlm.nih.gov/37695588/

Women's Preventive Services Initiative. (2023). Screening for gestational diabetes mellitus. American College of Obstetricians and Gynecologists. https://www.womenspreventivehealth.org/recommendations/screening-for-gestational-diabetes-mellitus/

Yang, X., Han, R., Xiang, Z., Li, H., Zhao, Q., Chen, L., & Gao, L. (2023). Clinical practice guidelines on physical activity and exercise for pregnant women with gestational diabetes mellitus: A systematic review. International Journal of Nursing Practice, 29(6), e13141. https://doi.org/10.1111/ijn.13141

Zera, C., & Brown, F. M. (2025). Preexisting (pregestational) diabetes mellitus: Antenatal glycemic management. UpToDate. Retrieved June 10, 2025, from https://www.uptodate.com/contents/preexisting-pregestational-diabetes-mellitus-antenatal-glycemic-management

Zhou, T., Du, S., Sun, D., Li, X., Heianza, Y., Hu, G., Sun, L., Pei, X., Shang, X., & Qi, L. (2022). Prevalence and trends in gestational diabetes mellitus among women in the United States 2006–2017: A population-based study. Frontiers in Endocrinology, 13(article 868094). https://doi.org/10.3389/fendo.2022.868094

Powered by Froala Editor